The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Over the past month since the Carter Albrecht story hit the press there has been plenty of attention paid to the stop smoking aid Chantix. I am sure that most of it is not the kind of publicity that manufacturer Pfizer was hoping for as they launched their new add campaign. Our law office has been contacted by numerous people over the past month with claims of serious adverse reactions to Chantix. We have had several claims of suicidal ideation and plethora of other ailments that are believed to be caused by Chantix.

If you have not yet heard the about Chantix then I will give a little overview. It was approved last year by the FDA to assist people in the process of quiting smoking. The initial results were far more successful than those of any other smoking cessation aid in the past. The most common side effects associated with teh drug are rather mild and do not pose any significant health threat; however, there have been some very bizarre side effects that seem to be somewhat rare but very dangerous, even life threatening.

Many have claimed to experience intense suicidal ideation with no history of previous inclination and as in the case of Albrecht some seem to simply loose it, in violent and psychotic episodes. Hard hitting news stories have been surfacing on local news channels throughout the country, and Good Morning America even did a peice on Albrecht’s death and the dangers associated with Chantix.

If you have had an adverse reaction to Chantix we would like to help you. We are exploring the possibility of litigation against pharmaceutical giant Pfizer and we would like to hear about your experience with Chantix.

For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.

Comments for this article are closed.